PHATHOM PHARMACEUTICALS INC. - COMMON STOCK

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

11 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

04 Nov 2024 07:00:14 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

28 Oct 2024 07:00:49 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

27 Oct 2024 11:00:40 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

29 Aug 2024 07:00:43 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

19 Aug 2024 07:00:19 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 07:00:08 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

30 Jul 2024 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

29 Jul 2024 06:59:41 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

18 Jul 2024 07:00:50 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

15 May 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

26 Mar 2024 07:00:05 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 Mar 2024 07:00:50 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

29 Feb 2024 07:00:49 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire